Mitchell Hull
- Oncology top 2%
- Peptidase Inhibition and Analysis 2
- Pharmacology top 1%
- Hepatology top 5%
- Surgery top 5%
- Epidemiology top 5%
-
- Ubiquitin and proteasome pathways 4
- Protein Degradation and Inhibitors 4
- Peroxisome Proliferator-Activated Receptors 2
-
- Hippo pathway signaling and YAP/TAZ 4
- Cellular Mechanics and Interactions 2
-
- SARS-CoV-2 and COVID-19 Research 2
-
- Virus-based gene therapy research 2
- Co-authors
- R. Marc LearnedMakoto MakishimaKevin D. LustigBei ShanDavid J. MangelsdorfJoyce J. RepaHua TuPeter Coward
- Cited by
- OncologyPharmacologyHepatology
- Journals
- ACS Chemical Biology (4 papers)SLAS DISCOVERY (2 papers)Journal of the American Chemical Society (2 papers)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Mitchell Hull
25 papers receiving 3.1k citations
Hit Papers
Peers
Comparison fields: 5 of 112
- Oncology 1.6k
- Pharmacology 284
- Hepatology 221
- Surgery 1.0k
- Epidemiology 637
Countries citing papers authored by Mitchell Hull
This map shows the geographic impact of Mitchell Hull's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell Hull with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell Hull more than expected).
Fields of papers citing papers by Mitchell Hull
This network shows the impact of papers produced by Mitchell Hull. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell Hull. The network helps show where Mitchell Hull may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mitchell Hull, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 13 | |
| 2 | 2023 | 7 | |
| 3 | 2023 | 3 | |
| 4 | 2023 | 1 | |
| 5 | 2021 | 11 | |
| 6 | 2021 | 63 | |
| 7 | 2021 | 44 | |
| 8 | Sulfur(VI) Fluoride Exchange (SuFEx)-Enabled High-Throughput Medicinal Chemistrybreakdown → | 2020 | 152 |
| 9 | 2020 | 45 | |
| 10 | 2020 | 38 | |
| 11 | 2020 | 11 | |
| 12 | 2019 | 25 | |
| 13 | 2019 | 6 | |
| 14 | 2018 | 125 | |
| 15 | 2017 | 52 | |
| 16 | 2017 | 12 | |
| 17 | 2017 | 35 | |
| 18 | 2014 | 31 | |
| 19 | 2006 | 16 | |
| 20 | Identification of a Nuclear Receptor for Bile Acidsbreakdown → | 1999 | 2206 |
About Mitchell Hull
Mitchell Hull is a scholar working on Infectious Diseases, Cell Biology, Molecular Biology, Biotechnology and Virology, having authored 26 papers that have together received 3.2k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (4 papers), Protein Degradation and Inhibitors (4 papers), Hippo pathway signaling and YAP/TAZ (4 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Virus-based gene therapy research (2 papers), Cellular Mechanics and Interactions (2 papers), Peptidase Inhibition and Analysis (2 papers) and Peroxisome Proliferator-Activated Receptors (2 papers). The work is most often cited by research in Oncology (1.6k citations), Pharmacology (284 citations), Hepatology (221 citations), Surgery (1.0k citations) and Epidemiology (637 citations). Mitchell Hull has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include R. Marc Learned, Makoto Makishima, Kevin D. Lustig, Bei Shan, David J. Mangelsdorf, Joyce J. Repa, Hua Tu, Peter Coward, Jürgen M. Lehmann and Emily Chen. Their work appears in journals such as ACS Chemical Biology, SLAS DISCOVERY, Journal of the American Chemical Society, Nature Communications and eLife.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.